Congress Park Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Congress Park Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-12,625	Closed	-$313K	–	98
2019 Q1	$313K	Sell	12,625 -5,050	-29%	-$127K	0.27%	72
2018 Q4	$317K	Buy	17,675 +530	+3%	+$10.8K	0.35%	62
2018 Q3	$504K	Buy	17,145 +2,700	+19%	+$105K	0.45%	55
2018 Q2	$657K	Buy	14,445 +9,830	+213%	+$478K	0.63%	45
2018 Q1	$244K	Buy	+4,615	New	+$269K	0.25%	84

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Congress Park Capital's CLVS Position: Q2 2019 in Review

Congress Park Capital sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 12,625 shares — an estimated $313K sold.

Congress Park Capital first reported a position in CLVS in Q1 2018 and held it in 5 quarters. The position peaked at $657K in Q2 2018. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

Congress Park Capital reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
Congress Park Capital sold 12,625 Clovis Oncology, Inc. shares in Q2 2019, an estimated $313K.
Congress Park Capital first reported a position in Clovis Oncology, Inc. in Q1 2018 and held it in 5 quarters.
Congress Park Capital's Clovis Oncology, Inc. position peaked at $657K in Q2 2018.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Congress Park Capital's 13F filing for Q2 2019, filed 2 Aug 2019.